( ubstantial risks and uncertainties in t...)Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment,Health

ubstantial risks and uncertainties in the process of development, commercialization, and regulatory review. There is no guarantee that the products will receive additional regulatory approvals. There is also no guarantee that the products will continue to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filing with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

(i) American Cancer Society, "Cancer Still a Heavy Burden for African

Americans,"

http://www.cancer.org/docroot/NWS/content/NWS_1_1x_Cancer_Still_a_Heavy_Burden

_for_African_Americans.asp (April 17, 2007).

(ii) American Cancer Society, "Cancer Facts & Figures for Hispanics/Latinos 2006-2008," p. 3.

(iii) Obasaju CK, Gonin R, Catalano RB, et al. Subgroup analysis of African American patients from a randomized Phase 3 trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in advanced (Stage IIB, IV) non-small cell lung cancer (Alpha Oncology trial A1-99002L). American Society of Clinical Oncology (ASCO) Annual Meeting 2007.

(iv) Obasaju CK, Kulkarni P, Wang Y, et al. Effect of race on the safety and efficacy of pemetrexed therapy in locally advanced and metastatic non- small cell lung cancer (NSCLC). American Society of Clinical Oncology (ASCO) Annual Meeting 2007.

CONTACT: Gregory L. Clarke of Eli Lilly and Company, +1-317-276-5222, ormobile, +1-317-554-7119, or ; or Neil Hochman, CPRWorldwide, +1-212-453-2067, or mobile, +1-516-784-9089, or gregory.clarke@lilly.com n.hochman@cprworldwideusa.com

Ticker Symbol: (:LLY)

'"/>

Page: 1 2 3 4 5 6 7 8 9 10 11
Related medicine technology :

1. Making Science Personal: Lilly Oncology to Unveil 76 Studies at ASCO 2007
2. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
3. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
4. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
5. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
6. Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of Blindness in Premature Infants
7. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
8. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
9. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
10. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
11. Eurands Zentase Effective in Treating Exocrine Pancreatic Insufficiency, Studies Show